16337 results for "free fc coins and points Visit Buyfc26coins.com Alennukset toistuvista ostoista..p4v2"

in 20.71 milliseconds.

• EGAD00000000059

  Aggregate results from 43 Carbamazepine-induced hypersensitivity syndrome patients and 1296 1958 British Birth Cohort control samples

  Dataset EGAD00000000059

• Summary data from case control analysis

  Summary data from GWAS analysis on 856 cases and 2836 control

  Dataset EGAD00000000115

• EGAD00010000692

  Genome-wide DNA methylation epigenotyping of African rainforest hunter-gatherers and neighbouring agriculturalists by Illumina HumanMethylation450

  Dataset EGAD00010000692

• BCC exomes and transcriptomes

  Dataset EGAD00001001857

• OGVP_HC24_Controls

  Healthy adult volunteers and newborns recruited in various countries across Oceania.

  Dataset EGAD00010000953

• Belgium-Immuno

  Belgium Multiple Sclerosis cases and normal controls

  Dataset EGAD00010002045

• France-Immuno

  France Multiple Sclerosis cases and normal controls

  Dataset EGAD00010002046

• AUSNZ-Immuno

  Australia and New Zealand Multiple Sclerosis case

  Dataset EGAD00010002047

• Germany-Immuno

  Germany Multiple Sclerosis cases and normal controls

  Dataset EGAD00010002044

• Time series analysis of neoadjuvant chemotherapy and bevacizumab treated breast carcinomas reveals a systemic shift in genomic aberrations

  Study EGAS00001003287

• Whole Exome Sequencing of Schizophrenia cases and controls performed at the Broad Institute on a cohort from Bristol, UK

  Study EGAS00001006274

• IMPRESS: Improved Methylation Profiling using Restriction Enzymes and smMIP Sequencing, Combined with New Biomarker Panel, Creating Multi-Cancer Detection Assay

  Study EGAS00001007559

• DNA polymerase and mismatch repair deficient cancers exert distinct genome-wide microsatellite signatures 2

  Study EGAS00001004816

• Single cell characterization of arrested B-lymphoid differentiation and leukemic cell states in ETV6-RUNX1-positive pediatric leukemia

  Study EGAS00001004374

• Clonal dynamics of normal hepatocyte expansions in homeostatic human livers and their association with the biliary epithelium

  Study EGAS00001005539

• Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models

  Study EGAS00001006134

• Complex patterns of genomic heterogeneity identified in 42 tumor samples and ctDNA of a pulmonary atypical carcinoid patient

  Study EGAS00001006530

• Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer

  Study EGAS00001007430

• DAC for DLBCL dataset

  Data Access Committee for cfDNA sequencing dataset from 290 samples from patients with DLBCL and HGBL.

  Dac EGAC50000000257

• Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

  Study EGAS00001004615

• Kerl Pediatric Oncology Münster

  Kerl lab at the Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany

  Dac EGAC50000000765

• An approach for evaluating the effects of dietary fiber polysaccharides on the human gut microbiome and plasma proteome

  Study EGAS00001005330

• WGS data for NRF2 study

  WGS data for cell lines and clinical samples

  Dataset EGAD00001002244

• A Phase I Study of the Treatment of Recurrent Malignant Glioma with CAN-3110 (AKA rQNestin34.5v.2), a Genetically Engineered HSV-1 Virus

  This study is a "first-in-human" phase 1 trial of recurrent, IDH wild-type glioblastoma (rGBM) patients treated with CAN-3110 (aka rQNestin34.5v.2), a genetically modified oncolytic herpes simplex virus 1 (HSV-1). The study was a 3+3 dose-escalation study starting at a single intra-tumoral injection of 106 PFU CAN-3110 going up to 1010 PFU in half-log increments (cohorts 1-9). An expansion cohort (cohort 10) was treated with 109 PFU injected into up to 5 sites within a single tumor. Principal findings of the study conclude that:CAN-3110 was safe at all tested doses (no dose-limiting toxicities reached)HSV-1 seropositive patients survived significantly longer than HSV-1 seronegative patients in this study - longer than expected based on historical rGBM controlsHSV-1 seropositive patients were significantly more likely to clear CAN-3110 (HSV-1) antigen from their tumors based on immunohistochemical stainingCAN-3110 treatment-induced CD8+/CD4+ T-cell recruitment to injected tumor sites altered TCR beta diversity in both tumor infiltrating leukocytes (TILs) and PBMCs, and initiated changes in specific TCR beta clonotypes and immune gene signatures which were associated with post-treatment survival.Data provided in dbGaP for this study include:Bulk RNA-Seq data for 13 pre/post-treatment pairs of rGBM tumors corresponding to 12 unique patients (patient 28 was treated with CAN-3110 at two different timepoints). This data is provided as raw sequencing reads (.fastq), kallisto pseudoalignment transcript-level read counts (abundance.tsv files), gene-level abundance matrix (Gene_Level_Expression_Matrix.tsv), and immune gene signature scores matrix (Immune_Gene_Signatures_Matrix.tsv). Sequencing was performed as paired 150bp sequencing on NovaSeq6000 S4 Illumina flow cells. Library preparation varied by batch as described in the included RNAseq_Metadata.xlsx table.TCR beta DNA sequencing performed by Adaptive Biotechnologies for 21 pre/post-treatment pairs of rGBM tumors and PBMCs representing 20 unique patients (patient 28 was treated with CAN-3110 at two different timepoints). Note that all tumor pairs with TCR beta sequencing data also have available bulk RNA-Seq data. The TCR beta sequencing data is provided as an excel spreadsheet (TCRbeta_Sample_Overview.xslx), which provides a broad level summary of the sequencing on a per-sample basis (# of TCRbeta templates, T cell fraction, TCR beta diversity metrics, etc.) and as a large tab separated value file (Full_TCRbeta_Rearrangement_Details.tsv), which provides information per sample at the level of each unique TCR beta sequence (amino/nucleic acid sequence, VDJ gene usage, etc.).An excel table of de-identified metadata for the patients involved in this study.

  Study phs003378

• Chair of Experimental Medicine and Therapy Research Regensburg DAC

  Dac EGAC00001001699